Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences’ (GILD) Global Healthcare Narrative?
Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for HIV prevention...
